Living donor liver transplantation for pediatric patients with metabolic disorders: The Japanese multicenter registry

Mureo Kasahara, Seisuke Sakamoto, Reiko Horikawa, Umeshita Koji, Koichi Mizuta, Masato Shinkai, Takahito Yagi, Tomoaki Taguchi, Yukihiro Inomata, Shinji Uemoto, Kuroda Tatsuo, Shunichi Kato

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

LDLT is indicated for a variety of metabolic disorders, primarily in Asian countries due to the absolute scarcity of deceased donor LT. We analyzed data for all pediatric LDLTs performed between November 1989 and December 2010, during which 2224 pediatric patients underwent LDLT in Japan. Of these patients, 194 (8.7%) underwent LDLT for metabolic disorders. Wilson's disease (n = 59; 30.4%) was the most common indication in the patients with metabolic disorders, followed by OTCD (n = 40; 20.6%), MMA (n = 20; 10.3%), and GSD (n = 15; 7.7%). The one-, five-, 10-, and 15-yr patient and graft survival rates were 91.2%, 87.9%, 87.0%, and 79.3%, and 91.2%, 87.9%, 86.1%, and 74.4%, respectively. Wilson's disease and urea cycle deficiency were associated with better patient survival. The use of heterozygous donors demonstrated no negative impact on either the donors or recipients. With regard to X-linked OTCD, symptomatic heterozygote maternal donors should not be considered potential donor candidates. Improving the understanding of the long-term suitability of this treatment modality will require the registration and ongoing evaluation of all patients with inherited metabolic disease considered for LT.

Original languageEnglish
Pages (from-to)6-15
Number of pages10
JournalPediatric Transplantation
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Living Donors
Liver Transplantation
Registries
Pediatrics
Tissue Donors
Hepatolenticular Degeneration
Metabolic Diseases
Graft Survival
Heterozygote
Urea
Japan
Survival Rate
Mothers
Survival

Keywords

  • liver transplantation
  • living donor liver transplantation
  • long-term results
  • metabolic disease
  • pediatric liver transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Living donor liver transplantation for pediatric patients with metabolic disorders : The Japanese multicenter registry. / Kasahara, Mureo; Sakamoto, Seisuke; Horikawa, Reiko; Koji, Umeshita; Mizuta, Koichi; Shinkai, Masato; Yagi, Takahito; Taguchi, Tomoaki; Inomata, Yukihiro; Uemoto, Shinji; Tatsuo, Kuroda; Kato, Shunichi.

In: Pediatric Transplantation, Vol. 18, No. 1, 02.2014, p. 6-15.

Research output: Contribution to journalArticle

Kasahara, M, Sakamoto, S, Horikawa, R, Koji, U, Mizuta, K, Shinkai, M, Yagi, T, Taguchi, T, Inomata, Y, Uemoto, S, Tatsuo, K & Kato, S 2014, 'Living donor liver transplantation for pediatric patients with metabolic disorders: The Japanese multicenter registry', Pediatric Transplantation, vol. 18, no. 1, pp. 6-15. https://doi.org/10.1111/petr.12196
Kasahara, Mureo ; Sakamoto, Seisuke ; Horikawa, Reiko ; Koji, Umeshita ; Mizuta, Koichi ; Shinkai, Masato ; Yagi, Takahito ; Taguchi, Tomoaki ; Inomata, Yukihiro ; Uemoto, Shinji ; Tatsuo, Kuroda ; Kato, Shunichi. / Living donor liver transplantation for pediatric patients with metabolic disorders : The Japanese multicenter registry. In: Pediatric Transplantation. 2014 ; Vol. 18, No. 1. pp. 6-15.
@article{5b518f35812b4e5eb601178c39abeb27,
title = "Living donor liver transplantation for pediatric patients with metabolic disorders: The Japanese multicenter registry",
abstract = "LDLT is indicated for a variety of metabolic disorders, primarily in Asian countries due to the absolute scarcity of deceased donor LT. We analyzed data for all pediatric LDLTs performed between November 1989 and December 2010, during which 2224 pediatric patients underwent LDLT in Japan. Of these patients, 194 (8.7{\%}) underwent LDLT for metabolic disorders. Wilson's disease (n = 59; 30.4{\%}) was the most common indication in the patients with metabolic disorders, followed by OTCD (n = 40; 20.6{\%}), MMA (n = 20; 10.3{\%}), and GSD (n = 15; 7.7{\%}). The one-, five-, 10-, and 15-yr patient and graft survival rates were 91.2{\%}, 87.9{\%}, 87.0{\%}, and 79.3{\%}, and 91.2{\%}, 87.9{\%}, 86.1{\%}, and 74.4{\%}, respectively. Wilson's disease and urea cycle deficiency were associated with better patient survival. The use of heterozygous donors demonstrated no negative impact on either the donors or recipients. With regard to X-linked OTCD, symptomatic heterozygote maternal donors should not be considered potential donor candidates. Improving the understanding of the long-term suitability of this treatment modality will require the registration and ongoing evaluation of all patients with inherited metabolic disease considered for LT.",
keywords = "liver transplantation, living donor liver transplantation, long-term results, metabolic disease, pediatric liver transplantation",
author = "Mureo Kasahara and Seisuke Sakamoto and Reiko Horikawa and Umeshita Koji and Koichi Mizuta and Masato Shinkai and Takahito Yagi and Tomoaki Taguchi and Yukihiro Inomata and Shinji Uemoto and Kuroda Tatsuo and Shunichi Kato",
year = "2014",
month = "2",
doi = "10.1111/petr.12196",
language = "English",
volume = "18",
pages = "6--15",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Living donor liver transplantation for pediatric patients with metabolic disorders

T2 - The Japanese multicenter registry

AU - Kasahara, Mureo

AU - Sakamoto, Seisuke

AU - Horikawa, Reiko

AU - Koji, Umeshita

AU - Mizuta, Koichi

AU - Shinkai, Masato

AU - Yagi, Takahito

AU - Taguchi, Tomoaki

AU - Inomata, Yukihiro

AU - Uemoto, Shinji

AU - Tatsuo, Kuroda

AU - Kato, Shunichi

PY - 2014/2

Y1 - 2014/2

N2 - LDLT is indicated for a variety of metabolic disorders, primarily in Asian countries due to the absolute scarcity of deceased donor LT. We analyzed data for all pediatric LDLTs performed between November 1989 and December 2010, during which 2224 pediatric patients underwent LDLT in Japan. Of these patients, 194 (8.7%) underwent LDLT for metabolic disorders. Wilson's disease (n = 59; 30.4%) was the most common indication in the patients with metabolic disorders, followed by OTCD (n = 40; 20.6%), MMA (n = 20; 10.3%), and GSD (n = 15; 7.7%). The one-, five-, 10-, and 15-yr patient and graft survival rates were 91.2%, 87.9%, 87.0%, and 79.3%, and 91.2%, 87.9%, 86.1%, and 74.4%, respectively. Wilson's disease and urea cycle deficiency were associated with better patient survival. The use of heterozygous donors demonstrated no negative impact on either the donors or recipients. With regard to X-linked OTCD, symptomatic heterozygote maternal donors should not be considered potential donor candidates. Improving the understanding of the long-term suitability of this treatment modality will require the registration and ongoing evaluation of all patients with inherited metabolic disease considered for LT.

AB - LDLT is indicated for a variety of metabolic disorders, primarily in Asian countries due to the absolute scarcity of deceased donor LT. We analyzed data for all pediatric LDLTs performed between November 1989 and December 2010, during which 2224 pediatric patients underwent LDLT in Japan. Of these patients, 194 (8.7%) underwent LDLT for metabolic disorders. Wilson's disease (n = 59; 30.4%) was the most common indication in the patients with metabolic disorders, followed by OTCD (n = 40; 20.6%), MMA (n = 20; 10.3%), and GSD (n = 15; 7.7%). The one-, five-, 10-, and 15-yr patient and graft survival rates were 91.2%, 87.9%, 87.0%, and 79.3%, and 91.2%, 87.9%, 86.1%, and 74.4%, respectively. Wilson's disease and urea cycle deficiency were associated with better patient survival. The use of heterozygous donors demonstrated no negative impact on either the donors or recipients. With regard to X-linked OTCD, symptomatic heterozygote maternal donors should not be considered potential donor candidates. Improving the understanding of the long-term suitability of this treatment modality will require the registration and ongoing evaluation of all patients with inherited metabolic disease considered for LT.

KW - liver transplantation

KW - living donor liver transplantation

KW - long-term results

KW - metabolic disease

KW - pediatric liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84891831528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891831528&partnerID=8YFLogxK

U2 - 10.1111/petr.12196

DO - 10.1111/petr.12196

M3 - Article

C2 - 24283623

AN - SCOPUS:84891831528

VL - 18

SP - 6

EP - 15

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 1

ER -